-
1.
公开(公告)号:US20120269812A1
公开(公告)日:2012-10-25
申请号:US13451135
申请日:2012-04-19
申请人: Jason BAUM , Bryan JOHNSON , Alexey Alexandrovich LUGOVSKOY , Lihui XU , Neeraj KOHLI , Jonathan Basil FITZGERALD , Sharlene ADAMS
发明人: Jason BAUM , Bryan JOHNSON , Alexey Alexandrovich LUGOVSKOY , Lihui XU , Neeraj KOHLI , Jonathan Basil FITZGERALD , Sharlene ADAMS
IPC分类号: C07K16/46 , A61P35/00 , C07H21/04 , A61K39/395
CPC分类号: C07K16/2863 , A61K2039/505 , C07K16/2869 , C07K16/30 , C07K16/32 , C07K16/40 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/565 , C07K2317/60 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
摘要翻译: 本文提供了可用作抗肿瘤剂并且特异性结合人IGF-1R和人ErbB3的新型单特异性和双特异性抗体。 示例性的抗体通过IGF-1R和ErbB3之一或两者抑制信号转导。 示例性的多价蛋白质包含至少一个抗IGF-1R结合位点和至少一个抗ErbB3结合位点。 在某些实施方案中,结合位点可以通过免疫球蛋白恒定区连接。 还提供了新的抗ErbB3和抗IGF-1R抗体(例如,单克隆抗体)。